High blood pressure that stays above target despite 3 or more medications used together — a 2018 GWAS across European and Hispanic cohorts found a genome-wide significant variant near MSX2.
Resistant hypertension is high blood pressure that remains above target despite taking 3 or more antihypertensive medications from different classes together, including a diuretic — or blood pressure that requires 4 or more medications to control. It carries a higher risk of cardiovascular complications than hypertension that responds to standard treatment.
This 2018 study searched for common genetic variants associated with resistant hypertension in cohorts of European and Hispanic ancestry. rs11749255, near MSX2, reached genome-wide significance in one of the study's analyses (226 European-ancestry and 143 Hispanic cases against 431 European-ancestry and 394 Hispanic controls): each copy of the risk allele (A) was associated with roughly 1.6 times the odds of resistant hypertension (95% CI 1.30–1.90, p=4×10⁻⁸). The same variant showed a weaker signal (p=3×10⁻⁷) in the study's larger, separate cohort (297 European-ancestry and 226 Hispanic cases against 623 European-ancestry and 633 Hispanic controls), where full odds-ratio figures for this specific SNP were not reported.
MSX2 is a developmental transcription factor gene, with an established role in bone and craniofacial development — its connection to blood pressure regulation is not obvious from its known biology, and this study does not propose a specific mechanism.
Resistant hypertension is diagnosed by blood pressure measurement against a defined medication regimen — not by genotype. rs11749255 is not used by any guideline to diagnose resistant hypertension or decide treatment in an individual.
Management follows standard hypertension care, escalated: confirming true resistance (ruling out poor adherence or measurement issues), screening for secondary causes, and adding or adjusting medications — decided by blood pressure readings and clinical assessment, not genotype. The variant on this page describes population-level risk found in a research study; it does not change how an individual case is managed.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Resistant Hypertension comes down to these specific, well-studied positions — not a diagnosis.
The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 2 of 6 linked studies with a resolved discovery ancestry.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Resistant Hypertension. MyGeneLog™. https://www.mygenelog.com/conditions/resistant-hypertension
Resistant hypertension is high blood pressure that stays above target despite 3 or more antihypertensive medications from different classes used together, including a diuretic.
Studying European and Hispanic-ancestry cohorts, it found a genome-wide significant variant near MSX2, with each risk allele copy linked to roughly 1.6 times the odds of resistant hypertension in its more fully reported analysis.
Not clearly. MSX2 has an established role in bone and craniofacial development, not an obvious connection to blood pressure -- this study found the statistical association without proposing a specific mechanism.
No. Diagnosis is by blood pressure measurement against a defined medication regimen, and management follows standard hypertension care — not genotype.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.